Eli Lilly's Dual-Pronged Strategy: A Pill Launch and a $6.3 Billion Bet

Eli Lilly launches oral weight-loss drug Foundayo, acquires Centessa for $6.3B, leveraging GLP-1 cash flow. Q1 earnings report due April 30.

Eli Lilly is entering a pivotal week, with its first-quarter earnings report on April 30 set against a backdrop of two major strategic moves: the full commercial rollout of its new weight-loss pill and a multi-billion dollar acquisition to dominate a new therapeutic area. The company is leveraging the immense cash flow from its blockbuster GLP-1 drugs to aggressively expand its reach.

The oral GLP-1 medication Foundayo (orforglipron) is now widely available across the United States. Since its April 9 launch, the drug has been shipped to pharmacies nationwide and integrated into telehealth platforms like Ro and LifeMD. Foundayo, approved for obesity and overweight, demonstrated an average weight reduction of 12.4% at its highest dose in the ATTAIN-1 study. Its pricing strategy is multifaceted: commercially insured patients may pay as little as $25 monthly with a savings card, while the cash price starts at $149 per month. Medicare patients are expected to gain access for $50 per month starting July 1, 2026.

This pricing reflects a political bargain. In exchange for introducing new drugs with more balanced pricing relative to other countries, Lilly has secured a three-year tariff exemption and protection from future price regulations from the U.S. government.

Foundayo enters a market where Novo Nordisk’s rival oral Wegovy pill arrived roughly three months earlier. While Wegovy showed a 16.6% average weight loss in its trials, Foundayo offers a practical advantage: it can be taken at any time without food or water restrictions. William Blair analyst Andy Hsieh views this as a key differentiator that could help close Novo Nordisk’s head start. Sales expectations are high; Morgan Stanley forecasts about $1.2 billion in U.S. revenue for Foundayo this year, with Bank of America projecting $2 billion.

Simultaneously, Lilly is making a massive bet on neuroscience. The company has signed a deal to acquire Centessa Pharmaceuticals for $38 per share, a 38% premium, valuing the transaction at $6.3 billion. An additional $1.5 billion in milestone payments is contingent on regulatory achievements. The acquisition, slated to close in Q3 2026, targets Centessa’s portfolio of Orexin receptor-2 agonists, which are designed to regulate sleep-wake cycles for conditions like narcolepsy and idiopathic hypersomnia.

Centessa’s lead candidate, Cleminorexton, has shown promise in Phase 2a studies. Oppenheimer analyst Kostas Biliouris estimates the total addressable market for such therapies could reach $15 to $20 billion, assuming roughly a quarter of patients seek treatment. This marks Lilly’s fourth acquisition in a year, a spree funded significantly by the GLP-1 giants Mounjaro and Zepbound, which together generated $36.5 billion in revenue last year.

The upcoming earnings report will provide the first financial snapshot of this ambitious period. Analysts expect Q1 adjusted earnings per share of $7.55, more than double the prior-year period, on revenue of approximately $17.6 billion. For the full year 2026, Lilly has guided for revenue between $80 and $83 billion, implying growth of about 25%.

Significant headwinds persist. The company anticipates a low-to-mid teen percentage price decline for its products in 2026, following a 7% drop in U.S. GLP-1 prices in Q4 2025. Research and marketing expenses are also climbing. Furthermore, Novo Nordisk recently released comparative data in April that positioned Wegovy favorably, a move that could influence prescribing patterns. The stock currently trades about 16% below its 52-week high of 959.50 euros, reflecting market caution. Analyst opinions are divided; Morgan Stanley recently raised its price target to $1,327, while HSBC maintains a Reduce rating with an $850 target.

Beyond the immediate launch and deal, Lilly’s global footprint is expanding. The company has submitted Foundayo for approval in over 40 countries, with plans for rapid launches post-approval. Since 2020, it has invested over $55 billion in production capacity, including a $3 billion commitment for a manufacturing facility in China over the next decade. How management addresses pricing pressures and integration costs on the April 30 earnings call will be crucial for investor confidence.